SABS icon

SAB Biotherapeutics
SABS

Overview Fund Activity

26 hedge funds and large institutions have $2.99M invested in SAB Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HWM
1
HB Wealth Management
Georgia
$358K
2
SOS
2
Silver Oak Securities
Tennessee
$29.9K
3
XT
3
XTX Topco
Cayman Islands
$22.3K
4
Renaissance Technologies
4
Renaissance Technologies
New York
$13.6K
5
Geode Capital Management
5
Geode Capital Management
Massachusetts
$114K

Top Sellers

1
Marshall Wace
1
Marshall Wace
United Kingdom
$0
2
DP
2
Diadema Partners
New Jersey
$0
3
Millennium Management
3
Millennium Management
New York
$22.1K
4
UBS Group
4
UBS Group
Switzerland
$106
5
TRCT
5
Tower Research Capital (TRC)
New York
$46
Name Holding Trade Value Shares
Change 		Shares
Change %
TRCT
26
Tower Research Capital (TRC)
New York
$46 -$1.09K -808 -96%
Marshall Wace
27
Marshall Wace
United Kingdom
– -$1.75M -459,168 Closed
DP
28
Diadema Partners
New Jersey
– -$114K -30,000 Closed
FDCDDQ
29
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$949 -250 Closed
1
2